Review Article
GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes
Pickart L, Margolina A. Cosmetics. 2018
Compare
GHK-Cu vs Ipamorelin
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
GHK-Cu
120 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Mood
226
Recovery
226
Energy
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
222
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
1
0.025–0.05 mg
16
0.2–0.4 mg
4
0.6–1 mg
1
1–2 mg
71
2–3 mg
87
3–5 mg
43
5+ mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 45 repeat reporters
Ipamorelin
102 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
236
Sleep
236
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
2
Headache
2
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
0.05–0.1 mg
12
0.1–0.2 mg
63
0.2–0.4 mg
137
0.4–0.6 mg
22
5+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 98% said they felt similar to their last entry, 2% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 44 repeat reporters
Sources (11)
Published sources linked on the GHK-Cu and Ipamorelin wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
GHK-Cu in wound healing and tissue regeneration
Pickart L. J Biomater Sci Polym Ed. 2008
- Wiki study page →Source
PubMed
GHK peptide as a natural modulator of multiple cellular pathways
Pickart L, Margolina A. Biomed Res Int. 2014
- Wiki study page →Source
ClinicalTrials.gov
GHK-Cu copper peptide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international. 2015
- Wiki study page →Source
PubMed
Biomimetic Hydrogel Scaffolds with Copper Peptide-Functionalized RADA16 Nanofiber Improve Wound Healing in Diabetes
Yang X, Zhang Y, Huang C, et al. Macromolecular bioscience. 2022
- Wiki study page →Source
PubMed
Ipamorelin, a new growth hormone-releasing peptide
Johansen PB, Nowak J, Skjaerbaek C, et al. Eur J Endocrinol. 2001
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
Ipamorelin growth hormone studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. European journal of endocrinology. 1998
- Wiki study page →Source
PubMed
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
Lu Z, Ngan MP, Liu JYH, et al. Physiology & behavior. 2024